4-methoxydibenzo[b,d]furan-1-carbothioamide | 1236068-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 4-methoxydibenzo[b,d]furan-1-carbothioamide
• 英文别名: 4-methoxydibenzofuran-1-carbothioamide
• CAS: 1236068-06-6
• 化学式: C₁₄H₁₁NO₂S
• 分子量: 257.313
• InChiKey: ODTIFKASMGUREE-UHFFFAOYSA-N

物化性质

• 沸点：
  447.6±55.0 °C(predicted)
• 密度：
  1.346±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  80.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methoxydibenzo[b,d]furan-1-carbothioamide 在 水 、 potassium hydroxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors

  摘要：

  Herein we report the synthesis, PDE-4B and TNF-alpha inhibitory activities of a few dibenzo[b,d]furan-1-yl-thiazole derivatives. The hydroxycyclohexanol amide derivatives 14, 18, 24, 29, 31 and 33 exhibited promising in vitro PDE-4B and TNF-alpha inhibitory activities. Compound 24 showed good systemic availability in preclinical animal models and was also found to be non-toxic (exploratory mutagenicity test). Further it exhibited promising results in in vivo asthma/COPD and Uveitis models. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.011
• 作为产物：
  描述：

  4-methoxydibenzo[b,d]furan 、 potassium thioacyanate 在 ice 、 正己烷 作用下， 以 甲烷磺酸 为溶剂， 反应 3.0h， 以to furnish the required product in 70% yield的产率得到4-methoxydibenzo[b,d]furan-1-carbothioamide
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS

  摘要：

  化合物的公式（I），它们的衍生物，类似物，互变异构体，区域异构体，立体异构体，多晶形，溶剂化物，中间体，药学上可接受的盐，药物组合物，N-氧化物，代谢物和其前药。这些化合物是磷酸二酯酶4型（PDE4）抑制剂。它们在治疗各种过敏性或炎症性疾病方面很有用，包括哮喘，COPD，慢性支气管炎，特应性皮炎，过敏性鼻炎，过敏性结膜炎，春季性结膜炎，牛皮癣，类风湿性关节炎，溃疡性结肠炎，克罗恩病，葡萄膜炎和红斑狼疮。

  公开号：

  US20110269753A1

文献信息

• Heterocyclic compounds as phosphodiesterase inhibitors
  申请人：Balasubramanian Gopalan

  公开号：US08580795B2

  公开（公告）日：2013-11-12

  Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.

  化合物的公式(I)、它们的衍生物、类似物、互变异构体、区域异构体、立体异构体、多晶形、溶剂物、中间体、药学上可接受的盐、药物组合物、N-氧化物、代谢物和其前药。这些化合物是磷酸二酯酶4型（PDE4）抑制剂。它们对治疗各种过敏或炎症性疾病有用，包括哮喘、慢性阻塞性肺病、慢性支气管炎、特应性皮炎、过敏性鼻炎、过敏性结膜炎、春季结膜炎、牛皮癣、类风湿性关节炎、溃疡性结肠炎、克罗恩病、葡萄膜炎和狼疮。
• [EN] HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：ORCHID RES LAB LTD

  公开号：WO2010084402A3

  公开（公告）日：2011-01-13
• US8580795B2
  申请人：——

  公开号：US8580795B2

  公开（公告）日：2013-11-12
• In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors
  作者：Gopalan Balasubramanian、Sukunath Narayanan、Lavanya Andiappan、Thirunavukkarasu Sappanimuthu、Saravanan Thirunavukkarasu、Shamundeeswari Sundaram、Saravanakumar Natarajan、Naresh Sivaraman、Sridharan Rajagopal、Fakrudeen Ali Ahamed Nazumudeen、Sanjeev Saxena、Santosh L. Vishwakarma、Shridhar Narayanan、Ganapavarapu V.R. Sharma、Chidambaram V. Srinivasan、Narasimhan Kilambi

  DOI：10.1016/j.bmc.2016.09.011

  日期：2016.11

  Herein we report the synthesis, PDE-4B and TNF-alpha inhibitory activities of a few dibenzo[b,d]furan-1-yl-thiazole derivatives. The hydroxycyclohexanol amide derivatives 14, 18, 24, 29, 31 and 33 exhibited promising in vitro PDE-4B and TNF-alpha inhibitory activities. Compound 24 showed good systemic availability in preclinical animal models and was also found to be non-toxic (exploratory mutagenicity test). Further it exhibited promising results in in vivo asthma/COPD and Uveitis models. (C) 2016 Elsevier Ltd. All rights reserved.
• HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
  申请人：Balasubramanian Gopalan

  公开号：US20110269753A1

  公开（公告）日：2011-11-03

  Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.

  化合物的公式（I），它们的衍生物，类似物，互变异构体，区域异构体，立体异构体，多晶形，溶剂化物，中间体，药学上可接受的盐，药物组合物，N-氧化物，代谢物和其前药。这些化合物是磷酸二酯酶4型（PDE4）抑制剂。它们在治疗各种过敏性或炎症性疾病方面很有用，包括哮喘，COPD，慢性支气管炎，特应性皮炎，过敏性鼻炎，过敏性结膜炎，春季性结膜炎，牛皮癣，类风湿性关节炎，溃疡性结肠炎，克罗恩病，葡萄膜炎和红斑狼疮。